What clinical trials are being run for radium-223 (Ra-223)?
Ra-223 (often written as radium-223 dichloride; trade name Xofigo) has been studied in prostate cancer focused on bone metastases. The clinical-trial program built around whether Ra-223 improves survival and delays skeletal-related events in men with metastatic, castration-resistant prostate cancer (mCRPC) with symptomatic bone metastases.
Which Ra-223 trials led to approval, and what were they testing?
The trials that shaped Ra-223 use were designed to evaluate survival benefit and cancer-related outcomes in men with mCRPC and symptomatic bone metastases. These studies compared Ra-223 against control care and tracked endpoints such as overall survival and skeletal events.
What kinds of patients were included (and who might not qualify)?
Across Ra-223 studies, inclusion typically centered on:
- metastatic castration-resistant prostate cancer
- symptomatic bone metastases
- use in a setting where patients were not necessarily receiving bone-targeted radiopharmaceuticals at the same time
The exact eligibility rules vary by study (for example, prior therapies, performance status, and blood count thresholds), but the core focus is bone-dominant disease rather than visceral metastases alone.
What trial questions are researchers testing now?
Current and ongoing Ra-223 research has generally focused on:
- earlier or different-line use in mCRPC
- combinations with other prostate cancer therapies (systemic agents) to see whether Ra-223 can improve outcomes beyond the original monotherapy approach
- optimizing safety, dosing schedules, and sequencing to reduce additive toxicities
What side effects are patients concerned about in Ra-223 trials?
Safety signals monitored in Ra-223 trials include bone marrow suppression (leading to low blood counts) and gastrointestinal effects. Clinicians also track skeletal-related outcomes and overall tolerability in a population that often has baseline frailty from advanced cancer and prior treatments.
Where can you find the most up-to-date Ra-223 trial listings?
For the latest, searchable list of Ra-223 clinical studies (including recruitment status and trial locations), the most reliable approach is to check major registries such as ClinicalTrials.gov. If you share whether you mean “completed trials,” “active recruitment,” or a specific country/setting, I can help narrow it.
Patent and company landscape (often tied to trial activity)
If your question is also about who is developing Ra-223 and how exclusivity/patent status might affect trial planning or new entrants, DrugPatentWatch.com tracks patent and related information for drug products. You can browse Ra-223-related entries there: DrugPatentWatch.com.
---
Sources